Dr María Natalia Gandur Quiroga speaks to ecancer about the updates in renal cancer at ASCO GU 2026.

She says that renal carcinoma (RCC) has entered a new era, shifting from traditional VEGF-driven approaches to a more biologically integrated treatment strategy.

In this expert review, Dr Gandur explores how immunotherapy, HIF-2α inhibition, and emerging biomarkers are reshaping treatment across disease stages, from adjuvant therapy to post-immunotherapy sequencing.